Feedback
Settings

Settings

Goto Application

1. WO2021050580 - CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF

Submit observation
PermaLink
Publication Number WO/2021/050580
Publication Date 18.03.2021
International Application No. PCT/US2020/049986
International Filing Date 09.09.2020
IPC
A61K 31/4365 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4365the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/4436 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4436containing a heterocyclic ring having sulfur as a ring hetero atom
A61K 31/444 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
CPC
C07D 495/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
495Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • MIRATI THERAPEUTICS, INC. [US]/[US]
Inventors
  • RAEPPEL, Franck
  • RAEPPEL, Stephane, L.
Agents
  • POLYAKOV, Mark, V.
  • MCLAUGHLIN, F., William
  • KATZ, Martin, L.
  • CLARK, Jeffrey, L.
  • GEIMER, Stephen, D.
Priority Data
62/898,46910.09.2019US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF
(FR) FORME CRISTALLINE D'UN INHIBITEUR DE LA TYROSINE KINASE MULTIPLE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
Abstract
(EN) The present invention relates to crystalline forms of N-(3 -fluoro-4-((2-(5-(((2- methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4- fluorophenyl)cyclopropane- 1,1 -di carboxamide (Compound 1), pharmaceutical compositions comprising the crystalline form, processes for preparing the crystalline form and methods of use therefore.
(FR) La présente invention concerne des formes cristallines de N-(3 -fluoro-4-((2-(5-(((2- méthoxyéthyl)amino)méthyl)pyridin-2-yl)thiéno[3,2-b]pyridin-7-yl)oxy)phényl)-N-(4-fluorophényl)cyclopropane-1,1-di carboxamide (composé 1), des compositions pharmaceutiques comprenant la forme cristalline, des procédés de préparation de la forme cristalline et des procédés d'utilisation de ceux-ci.
Related patent documents
CA3150267
CN114401720
EP2020862121This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau
# -